SG83747A1 - Substituted thiazolidinedione derivatives - Google Patents

Substituted thiazolidinedione derivatives

Info

Publication number
SG83747A1
SG83747A1 SG9904980A SG1999004980A SG83747A1 SG 83747 A1 SG83747 A1 SG 83747A1 SG 9904980 A SG9904980 A SG 9904980A SG 1999004980 A SG1999004980 A SG 1999004980A SG 83747 A1 SG83747 A1 SG 83747A1
Authority
SG
Singapore
Prior art keywords
thiazolidinedione derivatives
substituted thiazolidinedione
substituted
derivatives
thiazolidinedione
Prior art date
Application number
SG9904980A
Other languages
English (en)
Inventor
William Tremper Alan
Ripley Pool Colin
David Brightwell Malcolm
Sherwood Roman Robin
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10721461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG83747(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of SG83747A1 publication Critical patent/SG83747A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
SG9904980A 1992-09-05 1993-09-01 Substituted thiazolidinedione derivatives SG83747A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929218830A GB9218830D0 (en) 1992-09-05 1992-09-05 Novel compounds

Publications (1)

Publication Number Publication Date
SG83747A1 true SG83747A1 (en) 2001-10-16

Family

ID=10721461

Family Applications (2)

Application Number Title Priority Date Filing Date
SG1996008773A SG48302A1 (en) 1992-09-05 1993-09-01 Substituted thiazolidinedione deriatives
SG9904980A SG83747A1 (en) 1992-09-05 1993-09-01 Substituted thiazolidinedione derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG1996008773A SG48302A1 (en) 1992-09-05 1993-09-01 Substituted thiazolidinedione deriatives

Country Status (38)

Country Link
US (1) US5910592A (ko)
EP (2) EP0960883A1 (ko)
JP (5) JP2828777B2 (ko)
KR (3) KR20030097596A (ko)
CN (4) CN1040323C (ko)
AP (1) AP513A (ko)
AT (1) ATE182147T1 (ko)
AU (1) AU674880B2 (ko)
BR (1) BR1100916A (ko)
CA (2) CA2143849C (ko)
CY (1) CY2138B1 (ko)
CZ (2) CZ287473B6 (ko)
DE (2) DE10199002I2 (ko)
DK (1) DK0658161T3 (ko)
ES (1) ES2133410T3 (ko)
FI (2) FI106263B (ko)
GB (1) GB9218830D0 (ko)
GR (1) GR3030794T3 (ko)
HK (1) HK1012363A1 (ko)
HU (2) HU224212B1 (ko)
IL (1) IL106904A (ko)
LU (1) LU90712I2 (ko)
MA (1) MA22970A1 (ko)
MX (1) MX9305397A (ko)
MY (1) MY111190A (ko)
NL (1) NL300035I2 (ko)
NO (4) NO303016B1 (ko)
NZ (1) NZ255505A (ko)
PL (1) PL173725B1 (ko)
RU (3) RU2128179C1 (ko)
SA (1) SA93140245B1 (ko)
SG (2) SG48302A1 (ko)
SI (1) SI9300452B (ko)
SK (1) SK280777B6 (ko)
TW (1) TW385309B (ko)
UA (1) UA41901C2 (ko)
WO (1) WO1994005659A1 (ko)
ZA (1) ZA936509B (ko)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9308487D0 (en) * 1993-04-23 1993-06-09 Smithkline Beecham Plc Novel compounds
ZA973850B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5889032A (en) * 1996-05-06 1999-03-30 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
BR9711098B1 (pt) * 1996-07-01 2011-10-04 compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas.
USRE39266E1 (en) * 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6114526A (en) 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
CA2260044A1 (en) * 1996-07-12 1998-01-22 Stephen Alistair Smith Novel treatment of leptine resistance
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
WO1998057649A1 (en) * 1997-06-18 1998-12-23 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and sulphonylurea
SI0996444T1 (sl) * 1997-06-18 2007-08-31 Smithkline Beecham Plc Zdravljenje diabetesa s tiazolidindionom in metforminom
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US20010031776A1 (en) * 1997-10-13 2001-10-18 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
US20020006939A1 (en) * 1997-10-13 2002-01-17 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
GB9721693D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
GB9723295D0 (en) * 1997-11-04 1998-01-07 Smithkline Beecham Plc Novel process
US7091359B2 (en) 1997-11-04 2006-08-15 Smithkline Beecham Plc Process for the preparation of thiazolidinedione derivatives
GB9726563D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726568D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
AU770817B2 (en) * 1997-12-16 2004-03-04 Smithkline Beecham Plc 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl) thiazolidine-2,dione,maleic acid salt, hydrate as pharmaceutical
US20020137940A1 (en) * 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726566D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
AU774613B2 (en) * 1997-12-16 2004-07-01 Smithkline Beecham Plc Hydrate of 5-(4-(2- (N-methyl-N- (2-pyridil)amino) ethoxy)benzyl) thiazolidine-2,4-dione maleic acid salt
US6613785B2 (en) 1998-07-21 2003-09-02 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
MA26662A1 (fr) * 1998-07-21 2004-12-20 Smithkline Beecham Plc Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation
OA11579A (en) * 1998-07-21 2004-06-01 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing apoptosis.
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
AR023700A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Plc Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina
ID28783A (id) 1998-11-12 2001-07-05 Smithkline Beecham Plc Komposisi farmasi untuk pelepasan termodifikasi dari pemeka insulin dan zat antidiabetes lain
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
GB9909075D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
GB9909041D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
BR0009935A (pt) * 1999-04-23 2002-04-16 Smithkline Beecham Plc Produto farmacêutico
DE60037602T2 (de) 1999-04-23 2009-01-08 Smithkline Beecham P.L.C., Brentford Herstellung einer polymorphen Form eines Thiazolidindionderivates
SK286427B6 (sk) * 1999-04-23 2008-09-05 Smithkline Beecham Plc Polymorfná forma soli 5-[4-[2-(N-metyl-N-(2- pyridyl)amino)etoxy]benzyl]tiazolidín-2,4-diónu s kyselinou maleínovu, spôsob jej prípravy, farmaceutický prostriedok s jej obsahom a jej použitie
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
TR200200438T2 (tr) * 1999-08-17 2002-05-21 Smithkline Beecham P.L.C. Tiazolidindion türevleri içeren farmasötik terkipler ve bu terkipleri hazırlama prosesi.
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
GB0006133D0 (en) * 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
GB0014005D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
GB0014006D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
EA200300028A1 (ru) * 2000-06-16 2003-04-24 Смитклайн Бичам Плс Лечение и профилактика состояний, ассоциированных с сердечной инсулинорезистентностью
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
GB0019226D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0019223D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
AU2005229687B2 (en) * 2000-08-04 2008-03-13 Smithkline Beecham P.L.C. Tartrate salts of thiazolidinedione derivative
GB0019224D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
AU2005229688B2 (en) * 2000-08-04 2008-04-03 Smithkline Beecham P.L.C. Tartrate salts of thiazolidinedione derivative
GB0019228D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0021784D0 (en) * 2000-09-05 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021785D0 (en) * 2000-09-05 2000-10-18 Smithkline Beecham Plc Novel Pharmaceutical
GB0021865D0 (en) * 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
PL360661A1 (en) * 2000-09-26 2004-09-20 Dr.Reddy's Research Foundation Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
US7241895B2 (en) 2000-09-26 2007-07-10 Dr. Reddy's Laboratories Limited Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
GB0023971D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
ES2270955T3 (es) * 2000-12-22 2007-04-16 Smithkline Beecham Plc Sal mesilato de 5-(4-(2-(n-metil-n-(2-piridil)amino)etoxi)bencil)tiazolidina-2,4-diona.
WO2002051823A1 (en) 2000-12-26 2002-07-04 Torrent Pharmaceuticals Ltd Process for the preparation of rosiglitazone maleate
GB0127805D0 (en) 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
ES2266593T3 (es) * 2001-11-21 2007-03-01 Smithkline Beecham Plc Edisilatos de rosiglitazona y su uso como antidiabeticos.
CN100390170C (zh) * 2001-11-21 2008-05-28 史密斯克莱·比奇曼公司 5－(4－(2－(n－甲基－n－(2－吡啶基)氨基)乙氧基)苄基)噻唑烷－2,4－二酮苯磺酸盐，它的制备方法,其多晶型物ⅰ、ⅱ和ⅲ和它作为药物活性成分的用途
GB0129851D0 (en) * 2001-12-13 2002-01-30 Smithkline Beecham Plc Novel compounds
AU2002350965A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
WO2003050116A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129872D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
AU2002352479A1 (en) * 2001-12-20 2003-07-09 Smithkline Beecham Plc 5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus
GB0130510D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130511D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
WO2004062667A1 (en) * 2003-01-08 2004-07-29 Dr. Reddy's Laboratories Limited Amorphous form of rosiglitazone maleate and process for preparation thereof
GB0307259D0 (en) * 2003-03-28 2003-05-07 Glaxo Group Ltd Process
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
WO2005058813A2 (en) * 2003-12-17 2005-06-30 Ranbaxy Laboratories Limited Thiodiazolidinedione, oxazolidinedione and diazolidinedione derivatives and their use as antidiabetic agents
WO2005065654A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone formulations
EP1709038A2 (en) * 2004-01-28 2006-10-11 Usv Limited A process for the preparation of 5- 4- 2- n-methyl -n-(2-pyridyl) amino ethoxy phenyl methyl thiaz olidine-2, 4-dione maleate
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
GB2410948A (en) * 2004-02-13 2005-08-17 Sandoz Ag Novel phosphoric acid salt of rosiglitazone
GB2421240A (en) * 2004-12-14 2006-06-21 Sandoz Ag Phosphoric acid salt of rosiglitazone
CZ296468B6 (cs) * 2004-06-10 2006-03-15 Zentiva, A. S. Sul kyseliny fosforecné s 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dionema zpusob její prípravy
CZ296472B6 (cs) * 2004-07-27 2006-03-15 Zentiva, A. S Sul kyseliny stavelové s 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dionu azpusob její prípravy a její pouzití
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
DE102005034406A1 (de) * 2005-07-22 2007-02-01 Ratiopharm Gmbh Neue Salze von Rosiglitazon
KR100749219B1 (ko) * 2006-03-15 2007-08-13 건일제약 주식회사 신규한 로지글리타존 옥살산염, 이의 제조방법, 및 이를포함하는 약제학적 조성물
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
EP2213289A1 (en) 2006-09-07 2010-08-04 Nycomed GmbH Combination treatment for diabetes mellitus
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
EP1967182A1 (en) * 2007-03-07 2008-09-10 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a salt of rosigliatazone
SI2152663T1 (sl) 2007-06-04 2014-08-29 Ben Gurion University Of The Negev Research And Development Authority Tri-arilne spojine in sestavki, ki vsebujejo isto
CN101167726B (zh) * 2007-10-16 2011-05-18 宁夏康亚药业有限公司 马来酸罗格列酮分散片及其制备方法
PL384446A1 (pl) * 2008-02-12 2009-08-17 Adamed Spółka Z Ograniczoną Odpowiedzialnością Sól 5-[[4-[2-(metylo-2-pirydynyloamino)etoksy]fenylo]metylo]-2,4-tiazolidynodionu z kwasem malonowym i sposób jej wytwarzania
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate
DE102009053562A1 (de) 2009-11-18 2011-05-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
CN102532122B (zh) * 2010-12-29 2015-12-02 开封制药(集团)有限公司 酒石酸罗格列酮的制备方法
MX2016005995A (es) 2013-11-05 2016-08-17 Ben-Gurion Univ Of The Negev Res And Dev Authority Compuestos para el tratamiento de diabetes y complicaciones de la enfermedad derivadas de la misma.
US10034868B2 (en) 2014-11-04 2018-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
IT201800002630A1 (it) * 2018-02-13 2019-08-13 Giuliani Spa Composizione per la prevenzione e il trattamento dei disturbi della crescita dei capelli

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306228A1 (en) * 1987-09-04 1989-03-08 Beecham Group Plc Substituted thiazolidinedione derivatives
EP0415605A1 (en) * 1989-08-25 1991-03-06 Beecham Group p.l.c. Thiazolidinedione derivatives
WO1992007838A1 (en) * 1990-10-30 1992-05-14 Beecham Group Plc Thiazolidine dione derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4197297A (en) * 1976-11-17 1980-04-08 Smithkline Corporation 6-Halo-7,8-dihydroxy-1-(hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepines
US4405211A (en) * 1980-07-29 1983-09-20 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Liquid crystal compositions with pleochroic anthraquinone dyes
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5039687A (en) * 1985-12-04 1991-08-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyrrol-1-yl)pyridinamine compounds having enhancing activity
US5232925A (en) * 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306228A1 (en) * 1987-09-04 1989-03-08 Beecham Group Plc Substituted thiazolidinedione derivatives
EP0415605A1 (en) * 1989-08-25 1991-03-06 Beecham Group p.l.c. Thiazolidinedione derivatives
WO1992007838A1 (en) * 1990-10-30 1992-05-14 Beecham Group Plc Thiazolidine dione derivatives

Also Published As

Publication number Publication date
CZ56595A3 (en) 1995-11-15
SK27795A3 (en) 1995-08-09
KR950702982A (ko) 1995-08-23
UA41901C2 (uk) 2001-10-15
DE69325658T2 (de) 1999-12-30
DE10199002I2 (de) 2001-12-13
RU98117628A (ru) 2000-08-20
NO303016B1 (no) 1998-05-18
CZ287473B6 (en) 2000-12-13
CY2138B1 (en) 2002-06-21
JP2002047288A (ja) 2002-02-12
BR1100916A (pt) 2000-07-04
JP2008208142A (ja) 2008-09-11
FI951004A (fi) 1995-03-03
DK0658161T3 (da) 1999-11-29
SI9300452A (en) 1994-06-30
HU0500355D0 (en) 2005-05-30
ES2133410T3 (es) 1999-09-16
FI951004A0 (fi) 1995-03-03
AP9300562A0 (en) 1993-10-31
NO974646D0 (no) 1997-10-08
HUT72639A (en) 1996-05-28
JP2004359676A (ja) 2004-12-24
GB9218830D0 (en) 1992-10-21
SI9300452B (sl) 2003-02-28
CN1101911A (zh) 1995-04-26
ZA936509B (en) 1994-06-16
SA93140245B1 (ar) 2005-10-15
JPH08501095A (ja) 1996-02-06
CA2143849A1 (en) 1994-03-17
NO2001006I1 (no) 2001-04-30
NO2001005I2 (no) 2004-06-01
NO950852L (no) 1995-03-03
EP0960883A1 (en) 1999-12-01
EP0658161A1 (en) 1995-06-21
NL300035I1 (nl) 2001-03-01
IL106904A0 (en) 1993-12-28
LU90712I2 (fr) 2001-03-12
WO1994005659A1 (en) 1994-03-17
HU9500659D0 (en) 1995-04-28
FI982413A0 (fi) 1998-11-06
AU674880B2 (en) 1997-01-16
MY111190A (en) 1999-09-30
PL307812A1 (en) 1995-06-26
NL300035I2 (nl) 2001-07-02
RU95108329A (ru) 1996-12-20
RU2128179C1 (ru) 1999-03-27
CA2273147A1 (en) 1994-03-17
KR20080081099A (ko) 2008-09-05
JP2828777B2 (ja) 1998-11-25
CN1063942C (zh) 2001-04-04
TW385309B (en) 2000-03-21
KR100371297B1 (ko) 2003-05-09
PL173725B1 (pl) 1998-04-30
NZ255505A (en) 1997-08-22
NO974646L (no) 1995-03-03
EP0658161B1 (en) 1999-07-14
FI982413A (fi) 1998-11-06
MX9305397A (es) 1995-01-31
SG48302A1 (en) 1998-04-17
AP513A (en) 1996-07-30
DE69325658D1 (de) 1999-08-19
CN1183276A (zh) 1998-06-03
HU224212B1 (hu) 2005-06-28
FI106263B (fi) 2000-12-29
HK1012363A1 (en) 1999-07-30
KR20030097596A (ko) 2003-12-31
SK280777B6 (sk) 2000-07-11
AU4973093A (en) 1994-03-29
GR3030794T3 (en) 1999-11-30
NO305802B1 (no) 1999-07-26
CN1040323C (zh) 1998-10-21
ATE182147T1 (de) 1999-07-15
CA2143849C (en) 2000-04-25
CN1051312C (zh) 2000-04-12
JPH11147885A (ja) 1999-06-02
IL106904A (en) 1997-09-30
MA22970A1 (fr) 1994-04-01
CZ290591B6 (cs) 2002-08-14
CN1183275A (zh) 1998-06-03
US5910592A (en) 1999-06-08
RU98117673A (ru) 2000-07-20
CN1066939C (zh) 2001-06-13
CN1183413A (zh) 1998-06-03
NO950852D0 (no) 1995-03-03

Similar Documents

Publication Publication Date Title
CY2138B1 (en) Substituted thiazolidinedione derivatives
GB9305306D0 (en) Pyrrolo-pyridazione derivatives
HU9301955D0 (en) Benzophenone-hydrazone derivatives
GB9204958D0 (en) Thiazole derivatives
HU9300744D0 (en) 2-oxo-quinoline derivatives
ZA93324B (en) Heterocyclic derivatives
HU9301112D0 (en) Propenoyl-imidazole derivatives
GB2271564B (en) Thioalkylthio carbacephalosporin derivatives
GB2270913B (en) Chlordifluoromethoxyphenyl derivatives
ZA931516B (en) Substituted phenylquinazoline derivatives
EP0565961A3 (en) Ethyl-triazolyl derivatives
GB9202633D0 (en) Heterocyclic derivatives
GB9216783D0 (en) Heterocyclic derivatives
HU9302058D0 (en) Thia-diazinone derivatives
GB9223244D0 (en) Phenylpyrazine derivatives
GB9217301D0 (en) Substituted derivatives
GB9208382D0 (en) Substituted derivatives
GB9217960D0 (en) Heterocyclic derivatives
GB9216777D0 (en) Heterocyclic derivatives
GB9213825D0 (en) Heterocyclic derivatives
GB9226574D0 (en) Heterocyclic derivatives
GB9221989D0 (en) Heterocyclic derivatives
GB9217366D0 (en) Heterocyclic derivatives
GB9208418D0 (en) Heterocyclic derivatives
GB9204564D0 (en) Heterocyclic derivatives